Lilly’s Rheumatoid Arthritis Drug Shortens Covid-19 Hospitalization When Combined With Antiviral Med

Lilly’s Rheumatoid Arthritis Drug Shortens Covid-19 Hospitalization When Combined With Antiviral Med

The pharmaceutical company said its drug baricitinib, combined with remdesivir, reduces median hospital stays by one day compared to remdesivir alone, and is pursuing an emergency use authorization with the FDA.

Read More…

You May Also Like